Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 8/20 | 0.43 |
| ▸ | JUN | P05412 | 4/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.43 |
| ▸ | RELA | Q04206 | 4/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ATF1 | P18846 | 4/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8398500 | 0.81 | NFKB1 (0.53) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL1602748 | 0.81 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATR | |
| SCHEMBL30110408 | 0.81 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAATR | |
| SCHEMBL476310 | 0.77 | ALDH1A1 (0.59) | NFKB1ALDH1A1KDM4EATF1SYK | |
| SCHEMBL29922173 | 0.77 | ALDH1A1 (0.59) | NFKB1ALDH1A1KDM4EATF1SYK | |
| SCHEMBL3865834 | 0.77 | NFKB1 (0.43) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL4277492 | 0.77 | ATR (0.40) | NFKB1JUNNFKB2RELAATR | |
| SCHEMBL29827391 | 0.77 | NFKB1 (0.43) | NFKB1JUNNFKB2RELAALDH1A1 | |
| SCHEMBL22645507 | 0.75 | STK17B (0.40) | NFKB1JUNNFKB2RELASTK17B | |
| SCHEMBL1971986 | 0.75 | ATR (0.43) | ATRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125451-A1 | PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2021250531-A1 | 4-(4,5-DIHYDRO-1H-PYRAZOL-1-YL)PYRIMIDINE COMPOUND AS CANNABINOID RECEPTOR (CB1 RECEPTOR) ANTAGONISTS AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | 주식회사 종근당 | 2021-12-16 | — | — | WO | disclosed |
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247336-A1 | SUBSTITUTED PYRIMIDINES AS INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | NFKB1 1414/4885JUN 1878/4885NFKB2 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.